Taiwan's Money-Market Rate Slump May Delay Central Bank Easing
A surge in the Taiwanese dollar last month spurred an influx of funds, driving local money-market rates to the lowest level in more than a year and potentially delaying monetary easing by the central bank.
Taiwan's dollar has surged 11% since the end of March, which the central bank said was fueled by ' excessive ' inflows from exporters and foreign investors. Meanwhile, overseas buyers poured almost NT$220 billion ($7.4 billion) into local equities in May as the benchmark index gained. That's bolstered liquidity in the interbank market — and the highest interest rate that financial institutions pay to borrow for one week has slid to a 14-month low.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
24 minutes ago
- Bloomberg
Bloomberg: The Asia Trade 10/6/25
"Bloomberg: The Asia Trade" brings you everything you need to know to get ahead as the trading day begins in Asia. Bloomberg TV is live from Tokyo and Sydney with Shery Ahn and Haidi Stroud-Watts, getting insight and analysis from newsmakers and industry leaders on the biggest stories shaping global markets. (Source: Bloomberg)
Bloomberg
34 minutes ago
- Bloomberg
Toyota Industries Shareholders Question Buyout at Annual Meeting
Toyota Industries Corp. held what could be its last annual meeting as a public company, after the Toyota group unveiled plans to privatize the maker of forklifts, textile looms and auto parts. While the ¥4.7 trillion ($32.4 billion) buyout bid by an entity led by Toyota Motor Corp. Chairman Akio Toyoda wasn't formally on the agenda Tuesday, it overshadowed the gathering near Nagoya, Japan, as shareholders aired their grievances and sought clarity about the proposal.
Bloomberg
37 minutes ago
- Bloomberg
Chinese Firm Halts Production of Controversial Alzheimer's Drug
A Chinese company that developed the country's first homegrown Alzheimer's disease therapy has suspended production of the drug, a local media report said, casting doubts on the treatment's future nearly five years after its approval. Shanghai's Green Valley Pharmaceutical Co. informed employees of the production halt in an internal notice at the end of May, Yicai reported Monday, citing a person it didn't identify. The company failed to renew the drug's license and is currently waiting for regulatory review, the outlet reported, citing the source.
